Tomlinson Joy E, Tennant Bud C, Struzyna Alyssa, Mrad Dawn, Browne Nimet, Whelchel Dorothy, Johnson Philip J, Jamieson Camilla, Löhr Christiane V, Bildfell Robert, McKenzie Erica C, Laverack Melissa, Renshaw Randall W, Dubovi Edward, Kapoor Amit, Meirs Richard S, Belgrave Rodney, Engiles Julie, Van de Walle Gerlinde R, Divers Thomas J
Department of Microbiology and Immunology, Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, New York.
Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York.
J Vet Intern Med. 2019 Jan;33(1):258-265. doi: 10.1111/jvim.15362. Epub 2018 Dec 6.
A novel equine parvovirus (EqPV-H) was recently discovered in the equine liver with Theiler's disease.
To determine the prevalence of EqPV-H infection in naturally occurring Theiler's disease cases and in-contact horses in the absence of historical equine biologic product administration.
Ten cases of Theiler's disease from 6 separate properties were included in the study, based on the criteria of acute onset of clinical signs of liver failure with laboratory or histopathologic findings characteristic of Theiler's disease and no history of receiving an equine biologic product within the preceding 4 months. In addition, 37 in-contact horses from 4 of the 6 properties were screened for EqPV-H infection and hepatitis.
In prospective case series, cases were diagnosed with Theiler's disease by the attending veterinarian and were tested for EqPV-H by PCR of liver or serum. In-contact horses were assessed via serum chemistry and PCR at the attending veterinarian's discretion. Hepatitis was defined as serum gamma-glutamyltransferase activity above reference interval. The association of EqPV-H with hepatitis was determined by Fisher's exact test.
Nine of 10 (90%) Theiler's disease cases and 54% of tested in-contact horses were EqPV-H positive. Hepatitis was significantly associated with EqPV-H infection (P = .036).
Although further study is required to identify EqPV-H as the causative agent of Theiler's disease, EqPV-H appears strongly associated with cases of fatal Theiler's disease and subclinical hepatitis in horses in contact with those cases. The prevalence of EqPV-H infection on affected properties can be high.
最近在患有泰勒氏病的马肝脏中发现了一种新型马细小病毒（EqPV-H）。
确定在未使用过马生物制品的自然发生的泰勒氏病病例和接触马中EqPV-H感染的患病率。
根据肝衰竭临床症状急性发作且具有泰勒氏病特征性实验室或组织病理学检查结果，且在过去4个月内未接受过马生物制品的标准，纳入了来自6个不同马场的10例泰勒氏病病例进行研究。此外，对6个马场中4个马场的37匹接触马进行了EqPV-H感染和肝炎筛查。
在前瞻性病例系列中，由主治兽医诊断泰勒氏病病例，并通过肝脏或血清PCR检测EqPV-H。接触马由主治兽医根据血清化学和PCR进行评估。肝炎定义为血清γ-谷氨酰转移酶活性高于参考区间。通过Fisher精确检验确定EqPV-H与肝炎的关联。
10例泰勒氏病病例中有9例（90%）EqPV-H呈阳性，54%的检测接触马EqPV-H呈阳性。肝炎与EqPV-H感染显著相关（P = 0.036）。
尽管需要进一步研究以确定EqPV-H是否为泰勒氏病的病原体，但EqPV-H似乎与致命性泰勒氏病病例以及与这些病例接触的马的亚临床肝炎密切相关。受影响马场中EqPV-H感染的患病率可能很高。
